<DOC>
	<DOCNO>NCT00002499</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II/III trial study effectiveness combination chemotherapy treat child relapse acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Relapsed Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate feasibility , GATLA , study treatment ALL first hematologic relapse follow treatment BFM protocol . II . Evaluate efficacy induction vincristine/daunorubicin/asparaginase/prednisone produce second complete remission patient , evaluate toxicity regimen . III . Evaluate efficacy toxicity Capizzi I regimen ( vincristine/asparaginase/methotrexate ) Capizzi II regimen ( cytarabine/asparaginase/daunorubicin ) give maintain prolong complete remission . IV . Offer option bone marrow transplantation patient second remission histocompatible donor , compare outcome patient chemotherapy alone . OUTLINE : Nonrandomized study . Patients achieve remission Induction proceed Interim Maintenance , Continued Maintenance ; fail achieve remission receive Salvage Re-induction , follow , remission achieve , Interim Maintenance , Continued Maintenance . Induction : 4-Drug Combination Chemotherapy CNS Prophylaxis/Therapy . Vincristine , VCR , NSC-67574 ; Prednisone , PRED , NSC-10023 ; Asparaginase , ASP , NSC-109229 ; Daunorubicin , DNR , NSC-82151 ; Intrathecal Cytarabine , IT ARA-C , NSC-63878 ; Intrathecal Dexamethasone , IT DM , NSC-34521 . Interim Maintenance : 3-Drug Combination Chemotherapy , indicate , Radiotherapy . VCR ; ASP ; Methotrexate , MTX , NSC-740 ; , indicate , testicular irradiation ( equipment specify ) . Continued Maintenance : 3-Drug Combination Chemotherapy follow 3-Drug Combination Chemotherapy CNS Prophylaxis , indicate , Radiotherapy . Capizzi II : ARA-C ; ASP ; DNR ; follow Capizzi I : VCR ; ASP ; MTX ; IT ARA-C ; IT DM ; , indicate , cranial irradiation ( equipment specify ) . Salvage Re-induction : 2-Drug Combination Chemotherapy . ARA-C ; ASP . PROJECTED ACCRUAL : At least 72 evaluable patient enter . Accrual expect complete 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : ALL first hematologic relapse follow completion treatment BFM protocol ( ARGGATLA1LLA82 , 84 , 87 , 90 ) M2M3 bone marrow require PATIENT CHARACTERISTICS : Age : Under 20 Performance status : Not specify Life expectancy : Greater 8 week Hematopoietic : Not specify Hepatic : No significant liver disease Renal : No significant kidney disease Cardiovascular : No significant heart disease Pulmonary : No significant lung disease Other : No significant digestive disease PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior total anthracycline great 280 mg/sqm Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not applicable</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>May 2000</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
</DOC>